# Clinical Trials Data ERBB2 - Document 32

# Gastric Cancer Metastasized to the Central Nervous System (CNS)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01456455

"eligibilityCriteria": "Inclusion criteria:\n\n\* in order to be eligible for the study, the diagnosis of gastric cancer and/or lower esophageal cancer must be confirmed histologically. CNS involvement must be confirmed either via independent neuroradiological and/or positive CSF cytology.\n\nExclusion criteria:\n\n\* Patients whose diagnosis is not confirmed upon pathological review or where the CNS involvement cannot be confirmed after neuroradiological review will be excluded from this study.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "international",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, an ERBB2 gene mutation is not specifically mentioned as either an inclusion or exclusion factor. The eligibility is based on having a confirmed histological diagnosis of gastric cancer and/or lower esophageal cancer, with additional confirmation of CNS involvement.   
  
As there is no mention of ERBB2 gene mutation being required or being a disqualifying factor, a patient with such a mutation would not be excluded solely based on it. However, to determine eligibility, the patient must meet all the other specified criteria related to cancer type and CNS involvement.  
  
If there is specific concern about the mutation's impact on eligibility, further inquiry with the clinical trial coordinators would be advisable for more detailed information.